EGFR Inhibitor-Induced Folliculitis Decalvans: A Case Series and Management Guidelines

    January 2023 in “ Anti-Cancer Drugs
    Joanna Nowaczyk, Kamil Fret, Grażyna Kamińska‐Winciorek, Lidia Rudnicka, Joanna Czuwara
    TLDR Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
    This case series investigates three patients who developed folliculitis decalvans, a rare scarring alopecia, during afatinib therapy for cancer, highlighting the dermatological side effects of EGFR inhibitors. Patients aged 38 to 65 experienced scalp pruritus, erythema, and pustular lesions, with hair loss occurring after a median of 4 months. Diagnosis was confirmed via trichoscopy, and treatment with antibiotics like doxycycline and topical corticosteroids led to improvement. The study emphasizes early diagnosis and management to prevent irreversible hair loss. Management involves oral tetracyclines and topical treatments, with therapy lasting from 4 to 16 weeks or longer for persistent cases. Avoiding sun exposure is advised due to photosensitivity risks, and a proactive approach is crucial to maintain treatment compliance and avoid interruptions in anti-EGFR therapy.
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results

    Related Community Posts Join

    4 / 4 results

    Related Research

    2 / 2 results